peoplePerson
Angela DeMichele
Angela DeMichele led the first palbociclib clinical trial and co-leads the I-SPY 2 adaptive platform.
Medical oncologist who conducted the first-in-breast-cancer palbociclib study, co-leads I-SPY 2, and studies disseminated tumour cell dormancy as a target for preventing late recurrence.
Role
Co-Leader, Breast Cancer Research Program; Alan and Jill Miller Professor in Breast Cancer Excellence
Specialisms
Breast cancerCDK4/6 inhibitorsI-SPY 2 platform trialDormancy
Profiles
| Title | Journal | Year |
|---|---|---|
| CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment | Clinical Cancer Research | 2015 |